Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bei Fang

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Hepatology (Baltimore, Md.)|July 18, 2017
Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significanceXiao-Feng Li, Cheng Chen, Dai-Min Xiang, et al.
Plos One|November 17, 2011
Interactions between genetic variants in the adiponectin, adiponectin receptor 1 and environmental factors on the risk of colorectal cancerLi Liu, Rong Zhong, Sheng Wei, et al.
Lancet (London, England)|July 24, 2020
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialFeng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Hepatology (Baltimore, Md.)|July 18, 2017
Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significanceXiao-Feng Li, Cheng Chen, Dai-Min Xiang, et al.
Plos One|November 17, 2011
Interactions between genetic variants in the adiponectin, adiponectin receptor 1 and environmental factors on the risk of colorectal cancerLi Liu, Rong Zhong, Sheng Wei, et al.
Lancet (London, England)|July 24, 2020
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialFeng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, et al.
Pageof 7